This company listing is no longer active
Resumen de acción RFL
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Tyme Technologies, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.28 |
| 52 Week High | US$0.96 |
| 52 Week Low | US$0.20 |
| Beta | 0.92 |
| 1 Month Change | -16.41% |
| 3 Month Change | 22.50% |
| 1 Year Change | -68.08% |
| 3 Year Change | -82.10% |
| 5 Year Change | n/a |
| Change since IPO | -88.03% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| RFL | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 17.7% | 2.1% | -1.0% |
| 1Y | -68.1% | -22.4% | 2.0% |
Rentabilidad vs. Industria: RFL underperformed the German Biotechs industry which returned -9.5% over the past year.
Rentabilidad vs. Mercado: RFL underperformed the German Market which returned -25.4% over the past year.
Volatilidad de los precios
| RFL volatility | |
|---|---|
| RFL Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: RFL has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: RFL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2011 | 13 | Richie Cunningham | www.tymeinc.com |
Resumen de fundamentos de Tyme Technologies, Inc.
| Estadísticas fundamentales de RFL | |
|---|---|
| Capitalización bursátil | €49.40m |
| Beneficios(TTM) | -€24.14m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-2.0x
Ratio precio-beneficio (PE)¿Está RFL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de RFL | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$24.19m |
| Beneficios | -US$24.19m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.14 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado RFL a largo plazo?
Ver rendimiento histórico y comparativa